January 05, 2026 a 01:00 pm
TECH: Fundamental Ratio Analysis - Bio-Techne Corporation
Bio-Techne Corporation offers innovative solutions in the biotechnology sector, specifically focusing on protein science and diagnostic genomics. Despite challenges, the company's diverse product range and strategic initiatives position it well for future growth. Investors should consider both current market conditions and the company’s past performance while making investment decisions.
Fundamental Rating
The fundamental rating for Bio-Techne is derived from several key financial ratios and metrics. The scores below indicate a balanced assessment across different financial parameters.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 3 | |
| Return on Assets | 3 | |
| Debt to Equity | 2 | |
| Price to Earnings | 1 | |
| Price to Book | 2 |
Historical Rating
This table provides a snapshot of Bio-Techne's historical scores, offering insight into its performance over time.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-01-02 | 3 | 4 | 3 | 3 | 2 | 1 | 2 |
| Previous | 0 | 4 | 3 | 3 | 2 | 1 | 2 |
Analyst Price Targets
Current analyst price targets for Bio-Techne indicate a positive outlook, with a general consensus to buy.
| High | Low | Median | Consensus |
|---|---|---|---|
| 73 | 68 | 70 | 70.25 |
Analyst Sentiment
Analyst sentiment remains favorable, with a bias towards buying Bio-Techne shares, reflecting confidence in its growth potential.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 19 | |
| Hold | 6 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Bio-Techne Corporation shows promising potential in the biotechnology industry with a balanced fundamental score and positive analyst outlook. While its financial metrics demonstrate stability, the investment risk should always be carefully assessed against the backdrop of market volatility and economic conditions. The company's focus on innovative solutions in protein sciences and diagnostic genomics presents significant growth opportunities. Investors should remain cautious of fluctuating market environments affecting the biotech sector.